Cancer Immunology, Immunotherapy

, Volume 59, Issue 11, pp 1727–1737 | Cite as

Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice

  • Tae-Young Lee
  • Yang-Hyun Kim
  • Kyung-Soon Lee
  • Jeong-Ki Kim
  • Il-Han Lee
  • Jai-Myung Yang
  • Moon-Hee Sung
  • Jong-Sup Park
  • Haryoung Poo
Original Article


Given that local cell-mediated immunity (CMI) against the human papillomavirus type 16 E6 (HPV16 E6) protein is important for eradication of HPV16 E6-expressing cancer cells in the cervical mucosa, the HPV16 E6 protein may be a target for the mucosal immunotherapy of cervical cancer. Here, we expressed the HPV16 E6 antigen on Lactobacillus casei (L. casei) and investigated E6-specific CMI following oral administration of the L. casei-PgsA-E6 to mice. Surface expression of HPV16 E6 antigens was confirmed and mice were orally inoculated with the L. casei-PgsA or the L. casei-PgsA-E6. Compared to the L. casei-PgsA-treated mice, significantly higher levels of serum IgG and mucosal IgA were observed in L. casei-PgsA-E6-immunized mice; these differences were significantly enhanced after boost. Consistent with this, systemic and local CMI were significantly increased after the boost, as shown by increased counts of IFN-γ-secreting cells in splenocytes, mesenteric lymph nodes (MLN), and vaginal samples. Furthermore, in the TC-1 tumor model, animals receiving the orally administered L. casei-PgsA-E6 showed reduced tumor size and increased survival rate versus mice receiving control (L. casei-PgsA) immunization. We also found that L. casei-PgsA-E6-induced antitumor effect was decreased by in vivo depletion of CD4+ or CD8+ T cells. Collectively, these results indicate that the oral administration of lactobacilli bearing the surface-displayed E6 protein induces T cell-mediated cellular immunity and antitumor effects in mice.


HPV16 E6 Lactobacillus casei Antitumor effect PgsA Cell-mediated immunity 



Human papillomavirus


Poly-gamma-glutamic acid synthetase complex A


Interferon gamma


Enzyme-linked immunosorbent assay


Enzyme-linked immunospot


Standard deviation



This work was supported by grants of the Korea Health 21 R&D Project (A050562) and National R&D Program for Cancer Control (0720510), Ministry of Health and Welfare, Republic of Korea and a grant from KRIBB Initiative program to H. Poo.


  1. 1.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19CrossRefPubMedGoogle Scholar
  2. 2.
    zur Hausen H (1996) Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta 1288:F55–F78PubMedGoogle Scholar
  3. 3.
    zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698CrossRefPubMedGoogle Scholar
  4. 4.
    Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156CrossRefPubMedGoogle Scholar
  5. 5.
    de Villiers EM (1997) Papillomavirus and HPV typing. Clin Dermatol 15:199–206CrossRefPubMedGoogle Scholar
  6. 6.
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802CrossRefPubMedGoogle Scholar
  7. 7.
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527CrossRefPubMedGoogle Scholar
  8. 8.
    Matsukura T, Sugase M (1995) Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathologic lesions. Int J Cancer 61:13–22CrossRefPubMedGoogle Scholar
  9. 9.
    Crook T, Tidy JA, Vousden KH (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547–556CrossRefPubMedGoogle Scholar
  10. 10.
    Heck DV, Yee CL, Howley PM, Munger K (1992) Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89:4442–4446CrossRefPubMedGoogle Scholar
  11. 11.
    Doorbar J (2005) The papillomavirus life cycle. J Clin Virol 32(Suppl 1):S7–S15CrossRefPubMedGoogle Scholar
  12. 12.
    Ling M, Kanayama M, Roden R, Wu TC (2000) Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J Biomed Sci 7:341–356CrossRefPubMedGoogle Scholar
  13. 13.
    Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, Palefsky JM, Moscicki AB (2000) Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 182:595–598CrossRefPubMedGoogle Scholar
  14. 14.
    Nakagawa M, Kim KH, Moscicki AB (2005) Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol 12:1003–1005PubMedGoogle Scholar
  15. 15.
    Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M (2008) Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol 15:937–945CrossRefPubMedGoogle Scholar
  16. 16.
    Tjiong MY, Out TA, Ter Schegget J, Burger MP, Van Der Vange N (2001) Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review. Int J Gynecol Cancer 11:9–17CrossRefPubMedGoogle Scholar
  17. 17.
    Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL (2002) Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer 102:629–637CrossRefPubMedGoogle Scholar
  18. 18.
    Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P (1997) Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 65:3328–3336PubMedGoogle Scholar
  19. 19.
    Lee JS, Poo H, Han DP, Hong SP, Kim K, Cho MW, Kim E, Sung MH, Kim CJ (2006) Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 80:4079–4087CrossRefPubMedGoogle Scholar
  20. 20.
    Poo H, Pyo HM, Lee TY, Yoon SW, Lee JS, Kim CJ, Sung MH, Lee SH (2006) Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57BL/6 mice. Int J Cancer 119:1702–1709CrossRefPubMedGoogle Scholar
  21. 21.
    Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS (2008) An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26:1846–1854CrossRefPubMedGoogle Scholar
  22. 22.
    Thones N, Muller M (2007) Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 369:375–388CrossRefPubMedGoogle Scholar
  23. 23.
    Hanniffy S, Wiedermann U, Repa A, Mercenier A, Daniel C, Fioramonti J, Tlaskolova H, Kozakova H, Israelsen H, Madsen S, Vrang A, Hols P, Delcour J, Bron P, Kleerebezem M, Wells J (2004) Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 56:1–64CrossRefPubMedGoogle Scholar
  24. 24.
    Seegers JF (2002) Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 20:508–515CrossRefPubMedGoogle Scholar
  25. 25.
    Perdigon G, Maldonado Galdeano C, Valdez JC, Medici M (2002) Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 56(Suppl 4):S21–S26CrossRefPubMedGoogle Scholar
  26. 26.
    Ashiuchi M, Nawa C, Kamei T, Song JJ, Hong SP, Sung MH, Soda K, Misono H (2001) Physiological and biochemical characteristics of poly gamma-glutamate synthetase complex of Bacillus subtilis. Eur J Biochem 268:5321–5328CrossRefPubMedGoogle Scholar
  27. 27.
    Ashiuchi M, Soda K, Misono H (1999) A poly-gamma-glutamate synthetic system of Bacillus subtilis IFO 3336: gene cloning and biochemical analysis of poly-gamma-glutamate produced by Escherichia coli clone cells. Biochem Biophys Res Commun 263:6–12CrossRefPubMedGoogle Scholar
  28. 28.
    Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI (2002) Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 62:7234–7240PubMedGoogle Scholar
  29. 29.
    Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P (1999) Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 73:9063–9071PubMedGoogle Scholar
  30. 30.
    Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21–26PubMedGoogle Scholar
  31. 31.
    Kim TW, Lee TY, Bae HC, Hahm JH, Kim YH, Park C, Kang TH, Kim CJ, Sung MH, Poo H (2007) Oral administration of high molecular mass poly-gamma-glutamate induces NK cell-mediated antitumor immunity. J Immunol 179:775–780PubMedGoogle Scholar
  32. 32.
    Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC (2004) Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 78:8468–8476CrossRefPubMedGoogle Scholar
  33. 33.
    Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell S, Courtney AN, Gambhira R, Lomada D, Chopra AK, Sastry KJ (2007) Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine 25:3302–3310CrossRefPubMedGoogle Scholar
  34. 34.
    Frazer I (2002) Vaccines for papillomavirus infection. Virus Res 89:271–274CrossRefPubMedGoogle Scholar
  35. 35.
    Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6:148–158CrossRefPubMedGoogle Scholar
  36. 36.
    Vitini E, Alvarez S, Medina M, Medici M, de Budeguer MV, Perdigon G (2000) Gut mucosal immunostimulation by lactic acid bacteria. Biocell 24:223–232PubMedGoogle Scholar
  37. 37.
    Galdeano CM, Perdigon G (2006) The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 13:219–226CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Tae-Young Lee
    • 1
  • Yang-Hyun Kim
    • 1
  • Kyung-Soon Lee
    • 1
  • Jeong-Ki Kim
    • 1
  • Il-Han Lee
    • 2
  • Jai-Myung Yang
    • 3
  • Moon-Hee Sung
    • 4
  • Jong-Sup Park
    • 5
  • Haryoung Poo
    • 1
  1. 1.Viral Infectious Disease Research CenterKorea Research Institute of Bioscience and BiotechnologyDaejonKorea
  2. 2.Bioleaders CorporationDaejeonKorea
  3. 3.Department of Biological SciencesSogang UniversitySeoulKorea
  4. 4.Department of Bio and NanochemistryKookmin UniversitySeoulKorea
  5. 5.Department of Obstetrics and GynecologyThe Catholic UniversitySeoulKorea

Personalised recommendations